Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease

Taro Akihisa; Shun Manabe; Hiroshi Kataoka; Shiho Makabe; Rie Yoshida; Yusuke Ushio; Kentaro Watanabe; Masayo Sato; Ken Tsuchiya; Toshio Mochizuki; Kosaku Nitta

doi:10.34067/KID.0007342020

Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease

Kidney360. 2021 May 18;2(7):1148-1151. doi: 10.34067/KID.0007342020. eCollection 2021 Jul 29.

Authors

Affiliations

¹ Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
² Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.

Abstract

This is the first report to describe dose dependency in the effects of tolvaptan treatment for autosomal dominant polycystic kidney disease.The weight-adjusted average daily dose of tolvaptan was found to be a factor that significantly affected the change in eGFR.If a patient shows tolerance, increasing the tolvaptan dose to the maximum should be considered.

Keywords: ADPKD; cystic kidney disease; dose-dependent; estimated glomerular filtration rate; prognostic factor; renal prognosis; tolvaptan; total kidney volume.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antidiuretic Hormone Receptor Antagonists / therapeutic use
Glomerular Filtration Rate
Humans
Polycystic Kidney, Autosomal Dominant* / drug therapy
Prognosis
Tolvaptan / therapeutic use

Substances

Antidiuretic Hormone Receptor Antagonists
Tolvaptan